PMID- 26224587
OWN - NLM
STAT- MEDLINE
DCOM- 20170713
LR  - 20181202
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 52
IP  - 3
DP  - 2016 Jun
TI  - Cinacalcet therapy in patients affected by primary hyperparathyroidism associated 
      to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
PG  - 495-506
LID - 10.1007/s12020-015-0696-5 [doi]
AB  - Primary hyperparathyroidism is the main endocrinopathy associated with Multiple 
      Endocrine Neoplasia type 1 syndrome. Cinacalcet is a calcimimetic agent licensed 
      for the treatment of secondary hyperparathyroidism in patients with end-stage 
      renal disease, and for the reduction of marked hypercalcemia in patients with 
      parathyroid carcinoma and sporadic hyperparathyroidism requiring surgery but for 
      whom parathyroidectomy is contraindicated. It may provide a medical alternative 
      for the management of primary hyperparathyroidism in subjects affected by 
      Multiple Endocrine Neoplasia type 1. In this longitudinal, intervention study, 33 
      MEN1 patients had been enrolled, 10 males and 23 females with a mean age of 
      40 +/- 11.9 years, range 20-63. Primary hyperparathyroidism was the first clinical 
      manifestation in 12 patients. All subjects commenced with Cinacalcet 30 mg/day, 
      22 patients starting therapy with calcimimetics as an alternative to surgery, and 
      11 patients opting for the medication after the onset of persistent post-surgical 
      primary hyperparathyroidism. Duration of follow-up was 12 months. The results of 
      this study show significant reductions in serum calcium. The changes in hormonal 
      secretions of pituitary and gastroenteropancreatic glands were not significant, 
      demonstrating the overall safety of this drug in this disease. Cinacalcet has 
      been well tolerated by 28 patients, whereas five individuals complained of 
      heartburn and grade 1 nausea, which did not prevent the completion of the study. 
      In conclusion, Cinacalcet has resulted to be well tolerated and safe in patients 
      with MEN1 syndrome and the calcium homeostasis was stabilized.
FAU - Giusti, Francesca
AU  - Giusti F
AD  - Department of Surgery and Translational Medicine, University of Florence, Largo 
      Palagi 1, 50139, Florence, Italy.
FAU - Cianferotti, Luisella
AU  - Cianferotti L
AD  - Department of Surgery and Translational Medicine, University of Florence, Largo 
      Palagi 1, 50139, Florence, Italy.
FAU - Gronchi, Giorgio
AU  - Gronchi G
AD  - Department of Surgery and Translational Medicine, University of Florence, Largo 
      Palagi 1, 50139, Florence, Italy.
FAU - Cioppi, Federica
AU  - Cioppi F
AD  - Department of Surgery and Translational Medicine, University of Florence, Largo 
      Palagi 1, 50139, Florence, Italy.
FAU - Masi, Laura
AU  - Masi L
AD  - Department of Surgery and Translational Medicine, University of Florence, Largo 
      Palagi 1, 50139, Florence, Italy.
FAU - Faggiano, Antongiulio
AU  - Faggiano A
AD  - Department of Clinical Medicine and Surgery, Federico II University, Naples, 
      Italy.
FAU - Colao, Annamaria
AU  - Colao A
AD  - Department of Clinical Medicine and Surgery, Federico II University, Naples, 
      Italy.
FAU - Ferolla, Piero
AU  - Ferolla P
AD  - Department of Internal Medicine and Endocrine Sciences, University of Perugia, 
      Perugia, Italy.
FAU - Brandi, Maria Luisa
AU  - Brandi ML
AD  - Department of Surgery and Translational Medicine, University of Florence, Largo 
      Palagi 1, 50139, Florence, Italy. marialuisa.brandi@unifi.it.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150730
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Parathyroid Hormone)
RN  - SY7Q814VUP (Calcium)
RN  - UAZ6V7728S (Cinacalcet)
SB  - IM
MH  - Adenoma/blood/complications/*drug therapy/metabolism
MH  - Adult
MH  - Calcium/blood
MH  - Cinacalcet/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hyperparathyroidism, Primary/blood/*drug therapy/etiology
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/blood/complications/*drug therapy
MH  - Parathyroid Hormone/blood
MH  - Parathyroid Neoplasms/blood/complications/*drug therapy/metabolism
MH  - Parathyroidectomy
MH  - Young Adult
OTO - NOTNLM
OT  - Calcimimetic
OT  - Neuroendocrine tumor
OT  - PHPT
OT  - Pituitary tumor
EDAT- 2015/08/01 06:00
MHDA- 2017/07/14 06:00
CRDT- 2015/07/31 06:00
PHST- 2015/03/11 00:00 [received]
PHST- 2015/07/18 00:00 [accepted]
PHST- 2015/07/31 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
AID - 10.1007/s12020-015-0696-5 [pii]
AID - 10.1007/s12020-015-0696-5 [doi]
PST - ppublish
SO  - Endocrine. 2016 Jun;52(3):495-506. doi: 10.1007/s12020-015-0696-5. Epub 2015 Jul 
      30.